Karyopharm Therapeutics

Targeting Disease
at the Nuclear Pore

Discover Now

60th American Society of Hematology (ASH) Annual Meeting & Exposition

1-4
December
2018

American Society of Hematology

San Diego, California, USA
December 1-4, 2018

READ MORE

60th American Society of Hematology (ASH) Annual Meeting & Exposition

1-4
December
2018

American Society of Hematology

San Diego, California, USA
December 1-4, 2018

READ MORE

60th American Society of Hematology (ASH) Annual Meeting & Exposition

1-4
December
2018

American Society of Hematology

San Diego, California, USA
December 1-4, 2018

READ MORE

About Karyopharm

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases.

Learn More

Pipeline

Our Drug Candidates:
SINE Compounds and PAK4 Inhibitor

View Pipeline

Stock Quote (KPTI)

Investor Information

Service temporary unavailable

11.160

0.160  (1.45%)

2018-11-16 16:00:00

Previous Close 11.000
Open 10.910
Volume 394,067
Exchange NASDAQ
Day High 11.190
Day Low 10.640
52-Week High 21.710
52-Week Low 9.000

Publications

Scientific Papers, Posters and Presentations on Karyopharm pipeline compounds

Visit Archive

Papers

Posters & Presentations

Patient Resources

Learn More

USA
Karyopharm Therapeutics

  • Corporate Headquarters:
  • 85 Wells Ave., 2nd floor
  • Newton, MA 02459
  •  
  • Main Phone Number (USA)
  • 617-658-0600

GERMANY
Karyopharm Therapeutics

  • Sitz der Gesellschaft:
  • Karyopharm Europe GmbH
  • Franziska-Bilek-Weg 9
  • 80339 München
  • Germany
  •  
  • Tel.: +49 (0) 89–54 84 86-101
  • Fax: +49 (0) 89–54 84 86-200

ISRAEL
Karyopharm Israel Ltd.

  • 94 Yigal Alon St.
  • Building no. 2, 34th floor
  • Tel Aviv-Yafo,
  • Israel

© 2018 Karyopharm Therapeutics

Terms of Use Privacy Policy